



---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) or 12(g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**SUCAMPO PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State of Incorporation or Organization)

**13-3929237**  
(IRS Employer Identification No.)

**4520 East-West Highway,  
Suite 300  
Bethesda, Maryland**  
(Address of Principal Executive Offices)

**20814**  
(Zip Code)

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.

Securities Act registration statement file number to which this form relates: **333-135133**

Securities to be registered pursuant to Section 12(b) of the Act:

Title of Each Class  
to be so Registered

Name of Each Exchange on Which  
Each Class is to be Registered

**Class A common stock, \$0.01 par value per share**

**The NASDAQ Global Market**

Securities to be registered pursuant to Section 12(g) of the Act: **None**

---

---

INFORMATION REQUIRED IN REGISTRATION STATEMENT

**Item 1. Description of Registrant's Securities to be Registered.**

Information with respect to the Class A common stock, par value \$0.01 per share (the "Class A Common Stock"), of the Registrant is incorporated by reference to the section captioned "Description of Capital Stock" in Amendment No. 8 to the Registrant's registration statement on Form S-1 (No. 333-135133) as filed with the Securities and Exchange Commission on July 17, 2007, any amendments to such registration statement filed subsequently thereto, and any form of prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with such registration statement.

**Item 2. Exhibits.**

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on The NASDAQ Global Market and the securities registered hereby are not being registered pursuant to Section 12(g) of the Exchange Act.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: July 18, 2007

By: /s/ Kei S. Tolliver

Kei S. Tolliver  
Vice President of Business Development  
and Company Operations and Secretary